CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

RegulatoryapprovedMinjuvirituximablenalidomidePositive
AI Analysis

Summary

Minjuvi (tafasitamab) in combination with rituximab and lenalidomide has been listed on the Australian PBS as the first chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination for adults with relapsed or refractory follicular lymphoma.

Outcome Details

Listed on PBS as first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination for adults with relapsed or refractory follicular lymphoma

Importance:6/10
Sentiment:
0.80
immunotherapylymphomaPBS approvalchemotherapy-freeregulatory approval
Related Companies
$TRAX

Read the original article

Published by PR Newswire Pharma on August 2, 2026 2:01 PM

Read Original